Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 9359437

Antibodies comprising chimeric constant domains

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jun 07 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 02 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353176

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9353163

Apelin fusion proteins and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 31 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 26 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9340594

VEGF antagonist formulations for intravitreal administration

REGENERON PHARMACEUTICALS, INC. · Granted Tue May 17 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 12 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9309326

Readily isolated bispecific antibodies with native immunoglobulin format

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9308256

Method of treating rheumatoid arthritis with an anti-IL-6R antibody

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 12 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 07 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9302015

Anti-PRLR antibodies and methods for killing PRLR-expressing cells

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9301509

Genetically modified mice and engraftment

REGENERON PHARMACEUTICALS, INC. · Granted Tue Apr 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 31 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9290574

Methods for treating eosinophilic esophagitis by administering an IL-4R inhibitor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 22 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 17 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9284380

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 15 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 10 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9273143

Methods and compositions comprising a combination of an anti-ErbB3 antibody and an anti-EG

REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 01 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 25 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9265827

Anti-PDGFR-beta antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 23 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 18 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9260515

Antibodies to human GDF8

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 16 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 11 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9254338

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 09 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 04 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9238692

Stabilized formulations containing anti-interleukin-4 receptor (IL-4R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 19 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 14 2036 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9228014

Antibodies capable of blocking the interaction between CD48 and a CD48 receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 05 2016 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 31 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9193801

Stabilized formulations containing anti-PCSK9 antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9193977

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 24 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9173880

Stabilized formulations containing anti-interleukin-6 receptor (IL-6R) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9150648

Anti-ASIC1 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Oct 06 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 01 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9139644

Modified chimeric polypeptides with improved pharmacokinetic properties

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 22 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 17 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9132192

Anti-EGFR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 15 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 10 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127068

Nucleic acids encoding human glucagon receptor antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 9127292

Non-human animals having a humanized signal-regulatory protein gene

REGENERON PHARMACEUTICALS, INC. · Granted Tue Sep 08 2015 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 03 2035 00:00:00 GMT+0000 (Coordinated Universal Time)

granted